HRP20160033T1 - Imunološka modulacija preko lectina tipa c - Google Patents

Imunološka modulacija preko lectina tipa c Download PDF

Info

Publication number
HRP20160033T1
HRP20160033T1 HRP20160033TT HRP20160033T HRP20160033T1 HR P20160033 T1 HRP20160033 T1 HR P20160033T1 HR P20160033T T HRP20160033T T HR P20160033TT HR P20160033 T HRP20160033 T HR P20160033T HR P20160033 T1 HRP20160033 T1 HR P20160033T1
Authority
HR
Croatia
Prior art keywords
antigen
reaction
clec9a
cell
composition
Prior art date
Application number
HRP20160033TT
Other languages
English (en)
Croatian (hr)
Inventor
David Sancho-Madrid
Oliver Schulz
Neil Charles Rogers
Caetano Reis E Sousa
Daniel Pennington
Olivier Pierre Joffre
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of HRP20160033T1 publication Critical patent/HRP20160033T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
HRP20160033TT 2007-07-20 2008-07-21 Imunološka modulacija preko lectina tipa c HRP20160033T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92999907P 2007-07-20 2007-07-20
GBGB0805159.1A GB0805159D0 (en) 2008-03-19 2008-03-19 Immune modulation via C-type lectin
PCT/GB2008/002504 WO2009013484A1 (en) 2007-07-20 2008-07-21 Immune modulation via c-type lectin
EP08776024.5A EP2185586B1 (en) 2007-07-20 2008-07-21 Immune modulation via c-type lectin

Publications (1)

Publication Number Publication Date
HRP20160033T1 true HRP20160033T1 (hr) 2016-02-26

Family

ID=39356783

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160033TT HRP20160033T1 (hr) 2007-07-20 2008-07-21 Imunološka modulacija preko lectina tipa c

Country Status (13)

Country Link
US (2) US8580266B2 (enExample)
EP (1) EP2185586B1 (enExample)
JP (1) JP5577246B2 (enExample)
CN (1) CN101896500B (enExample)
AU (1) AU2008278831B2 (enExample)
CA (1) CA2693277A1 (enExample)
DK (1) DK2185586T3 (enExample)
ES (1) ES2557935T3 (enExample)
GB (1) GB0805159D0 (enExample)
HR (1) HRP20160033T1 (enExample)
HU (1) HUE026387T2 (enExample)
SI (1) SI2185586T1 (enExample)
WO (1) WO2009013484A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815848A2 (pt) 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
US20110110861A1 (en) * 2008-05-13 2011-05-12 Mireille Hanna Lahoud Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
CA2755983A1 (en) * 2009-03-23 2010-09-30 The Walter And Eliza Hall Institute Of Medical Research Compounds and methods for modulating an immune response
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
KR20130036246A (ko) * 2010-05-07 2013-04-11 베일러 리서치 인스티튜트 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍
WO2013088136A1 (en) 2011-12-12 2013-06-20 Ahrens Susan Ligand for dngr-1 receptor
EP2901156B1 (en) 2012-09-26 2018-06-20 Cook Biotech Incorporated Medical device design, manufacture and testing systems
US20160015803A1 (en) * 2014-07-18 2016-01-21 Ross Kedl Immunostimulatory combinations and use thereof
AU2015294059B2 (en) * 2014-07-21 2019-03-14 Société des Produits Nestlé S.A. Nutritional products to promote safe swallowing for individuals with dysphagia
CN104789689B (zh) * 2015-05-13 2018-10-02 北京泱深生物信息技术有限公司 作为肺腺癌诊治靶标的clec9a基因
AU2016304597B2 (en) * 2015-08-06 2022-10-06 Memorial Sloan Kettering Cancer Center Methods and compositions for tumor therapy
CN115850521A (zh) * 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN105924501B (zh) * 2016-04-28 2019-04-02 郑州大学 靶向Clec9a的亲和肽WH肽
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
AU2018313810B2 (en) * 2017-08-09 2025-05-15 Orionis Biosciences BV Clec9A binding agents and use thereof
JPWO2019244973A1 (ja) * 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
MA53438A (fr) 2018-08-24 2021-09-15 Codiak Biosciences Inc Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
EP3908263A4 (en) * 2019-01-08 2023-04-19 University of Georgia Research Foundation, Inc. TARGETED NANOPARTICLES AND THEIR USES IN FUNGAL INFECTIONS
JP7546924B2 (ja) * 2019-03-01 2024-09-09 国立大学法人 筑波大学 アレルギー疾患を処置することに用いるための組成物
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
EP3892739A1 (en) * 2020-04-09 2021-10-13 Centre Léon Bérard Type iii interferon for use as a biomarker to predict response to a cancer treatment
GB202011859D0 (en) 2020-07-30 2020-09-16 Francis Crick Institute Ltd Cytosolic delivery
CA3248697A1 (en) 2022-04-21 2023-10-26 The Francis Crick Institute Limited BISPECIFIC LIAISON OFFICERS
WO2024018062A1 (en) 2022-07-21 2024-01-25 The Francis Crick Institute Limited Immunoconjugate
GB202401381D0 (en) 2024-02-02 2024-03-20 Francis Crick Institute Ltd Anti-actin antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055309A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10142994A1 (de) * 2001-09-01 2003-03-27 Keiper Gmbh & Co Längseinsteller für einen Fahrzeugsitz
CA2469941A1 (en) * 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
AU2008278831B2 (en) 2013-11-21
AU2008278831A1 (en) 2009-01-29
ES2557935T3 (es) 2016-01-29
US9205153B2 (en) 2015-12-08
SI2185586T1 (sl) 2016-02-29
US8580266B2 (en) 2013-11-12
CA2693277A1 (en) 2009-01-29
WO2009013484A1 (en) 2009-01-29
EP2185586A1 (en) 2010-05-19
EP2185586B1 (en) 2015-10-14
US20140328865A1 (en) 2014-11-06
CN101896500A (zh) 2010-11-24
GB0805159D0 (en) 2008-04-23
US20100221265A1 (en) 2010-09-02
DK2185586T3 (en) 2016-01-18
HUE026387T2 (en) 2016-05-30
JP5577246B2 (ja) 2014-08-20
JP2010534200A (ja) 2010-11-04
CN101896500B (zh) 2015-09-30

Similar Documents

Publication Publication Date Title
HRP20160033T1 (hr) Imunološka modulacija preko lectina tipa c
Yan et al. Applications of synthetic biology in medical and pharmaceutical fields
Lee et al. Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes
Khanam et al. Pathophysiology and treatment options for hepatic fibrosis: can it be completely cured?
Seo et al. Current strategies to enhance adipose stem cell function: an update
Suh et al. Therapeutic application of exosomes in inflammatory diseases
JP2010534200A5 (enExample)
Weissman et al. HPLC purification of in vitro transcribed long RNA
Ganesan et al. Targeting programmed Fusobacterium nucleatum Fap2 for colorectal cancer therapy
Schwarzenbach et al. Exosomes in immune regulation
Dargahi et al. Streptococcus thermophilus alters the expression of genes associated with innate and adaptive immunity in human peripheral blood mononuclear cells
Nagano et al. Crucial role of extracellular vesicles in bronchial asthma
Pestel et al. Pathogenic role of adipose tissue-derived mesenchymal stem cells in obesity and obesity-related inflammatory diseases
Beumer-Chuwonpad et al. The potential of tissue-resident memory T cells for adoptive immunotherapy against cancer
Dargahi et al. Immune modulatory effects of probiotic Streptococcus thermophilus on human monocytes
Kaur et al. The potential role of cytotoxic immune effectors in induction, progression and pathogenesis of amyotrophic lateral sclerosis (ALS)
Chen et al. CD4+ T-cell plasticity in non-infectious retinal inflammatory disease
Nekoua et al. Enteroviral pathogenesis of type 1 diabetes: the role of natural killer cells
Joo et al. Extracellular vesicles from thapsigargin-treated mesenchymal stem cells ameliorated experimental colitis via enhanced immunomodulatory properties
Zhang et al. Quantitative proteomic analysis of outer membrane vesicles from Fusobacterium nucleatum cultivated in the mimic cancer environment
Lei et al. Extracellular Vesicles and Their Role in Skin Inflammatory Diseases: From Pathogenesis to Therapy
Wang et al. Extracellular vesicles: From large-scale production and engineering to clinical applications
Garcia-Canaveras et al. CAR T-cells depend on the coupling of NADH oxidation with ATP production
Teng et al. Heat shock protein SSA1 enriched in hypoxic secretome of Candida albicans exerts an immunomodulatory effect via regulating macrophage function
Kozlova et al. A cap-optimized mRNA encoding multiepitope antigen ESAT6 induces robust cellular and humoral immune responses against Mycobacterium tuberculosis